Ernexa Therapeutics (NASDAQ:ERNA) Stock Price Down 5.1% – Here’s What Happened

Shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) traded down 5.1% on Monday . The company traded as low as $1.25 and last traded at $1.29. 32,715 shares traded hands during trading, a decline of 27% from the average session volume of 44,702 shares. The stock had previously closed at $1.36.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Ernexa Therapeutics Trading Down 5.1%

The company’s 50-day moving average price is $1.40 and its two-hundred day moving average price is $1.65. The company has a market cap of $10.13 million, a P/E ratio of -0.43 and a beta of 6.20.

Ernexa Therapeutics (NASDAQ:ERNA) last released its quarterly earnings data on Friday, November 7th. The company reported ($0.15) earnings per share for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP acquired a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.